{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:50:20Z","timestamp":1785790220377,"version":"3.56.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Malignant mesothelioma is a rare but highly aggressive malignancy associated with a poor prognosis. Similar to many other solid tumors, cytotoxic chemotherapy has traditionally been the standard treatment for patients with locally advanced or metastatic malignant pleural mesothelioma (MPM). However, with increasing recognition of immune dysregulation, immune-directed therapies have assumed a growing role in the management of mesothelioma. Here, we report a case of epithelioid-type malignant pleural mesothelioma that demonstrated primary resistance to ipilimumab plus nivolumab, followed by a marked metabolic response on 18F-FDG PET\/CT after switching to bevacizumab plus pemetrexed plus carboplatin.<\/jats:p>","DOI":"10.1097\/rlu.0000000000006495","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:02:41Z","timestamp":1777903361000},"page":"e824-e825","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Dramatic Morphometabolic Response to Bevacizumab-Based Chemotherapy After Immunotherapy Failure in Malignant Pleural Mesothelioma on FDG PET"],"prefix":"10.1097","volume":"51","author":[{"given":"Kevser","family":"Oksuzoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0705-4665","authenticated-orcid":false,"given":"Lutfu","family":"Perktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Onner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farise","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"R1-20260803","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/cancers17030503","article-title":"A meta-analysis of first-line treatments for unresectable pleural mesothelioma: indirect comparisons from reconstructed individual patient data of six randomized controlled trials","volume":"17","author":"Messori","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14737140.2017.1340157","article-title":"First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma","volume":"17","author":"Fujimoto","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"R4-20260803","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag","year":"2005","journal-title":"Chest"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"R6-20260803","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/2162402X.2019.1638211","article-title":"Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes","volume":"8","author":"Klampatsa","year":"2019","journal-title":"Oncoimmunology"},{"key":"R8-20260803","doi-asserted-by":"crossref","first-page":"104372","DOI":"10.1016\/j.critrevonc.2024.104372","article-title":"Evaluation of first-line and salvage therapies for unresectable malignant mesothelioma: a systematic review and network meta-analysis","volume":"198","author":"Zhuang","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"R9-20260803","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann Oncol"},{"key":"R10-20260803","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R11-20260803","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"key":"R12-20260803","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:02:14Z","timestamp":1785787334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006495","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"2026-01-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}